Genevieve Moyer, MD
Hematology and Oncology
Hemophilia & Thrombosis Center13199 E. Montview Blvd Suite 100, Aurora, CO 80045
UCHealth Blood Disorders and Cell Therapies Center - Anschutz Medical Campus1665 Aurora Court 3rd floor, Anschutz Cancer Pavilion, Aurora, CO 80045
UCHealth Anschutz Inpatient Pavilion - Anschutz Medical Campus12605 E. 16th Ave Aurora, CO 80045
I believe strongly in the importance of getting to know each patient as an individual and engaging them in shared decision making. To accomplish this, I strive to ensure that all my patients understand their diagnosis so that they feel empowered in the pursuit of their own health and wellness.
- Hematology and Oncology ( 2018 , 2018 )
- Internal Medicine ( 2014 )
Conditions & Treatments
Blood / Lymphatic System
Bleeding Disorders, Blood Disorders, Clotting Disorders
Interests & Activities
My medical specialty is classical hematology with an emphasis on hemostasis and thrombosis. I am committed to improving the management of women, transgender, and gender non-binary individuals with bleeding disorders. My primary research endeavors are focused on these populations with an overarching goal of developing novel risk stratification tools that can predict future bleeding and thrombotic events and help guide medical management.
Education & Training
MD, Saint Louis University School of Medicine (2011)
BS, Arizona State University (AZ) (2007)
MS, University of Colorado Denver (2018)
Saint Louis University School of Medicine Program (2015)
Saint Louis University School of Medicine Program (2018)
Research & Grants
Research Interests for Patients
At the time I entered my hematology/oncology fellowship, I was eager to pursue clinical research in the area of cancer-associated thrombosis. I chose to study the venous thromboembolism characteristics of individuals from our institution who received stem cell transplantation, focusing on differences between cord blood and non-cord blood recipients. I discovered that not only was post-transplant thrombosis a serious problem, but that these patients were also at an extremely high risk of bleeding with anticoagulation. As a result of this endeavor, I have developed a career interest aimed at developing tools to risk stratify complex patients regarding their risk for bleeding and clotting simultaneously. As my career has progressed, I have also discovered a passion for the treatment of women with bleeding disorders which has led to a goal of balancing our knowledge and understanding of bleeding disorders across genders. I continue to pursue the development of novel tools to aid in bleeding and clotting risk stratification while also spending time investigating these knowledge gaps regarding how to best care for women, transgender, and gender non-binary individuals with disorders of hemostasis.